|Bid||166.51 x 800|
|Ask||187.70 x 800|
|Day's Range||179.24 - 186.78|
|52 Week Range||151.80 - 195.81|
|Beta (3Y Monthly)||1.09|
|PE Ratio (TTM)||21.15|
|Earnings Date||Oct 22, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||213.05|
[Editor's note: "Check Out These 5 Fast-Growing Stocks to Buy " was previously published in June 2019. It has since been updated to include the most relevant information available.]The benefit of fast-growing stocks is self-evident, but if inflation becomes something to start worrying about, fast-growing stocks have an importance tied to timing.Source: Shutterstock If inflation returns, growth will be more uneven than it has been in the past. At that point, you'll need to find firms with solid sales earnings growth as well as technical and fundamental strengths to keep the profits rolling.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Stocks Ready to Bounce on a Trade Deal These are five fast-growing stocks to buy today that will keep you in good stead for years to come, even if inflation returns. Sherwin-Williams (SHW)Sherwin-Williams Co (NYSE:SHW) has sold paint and coatings now for 152 years. That's a pretty impressive record. But it's a bit unusual to see a paint company in a list of top growth stocks. Usually, it's some cloud-storage firm or a breakout online retailer.Source: Shutterstock However, SHW, by its size and reputation, has not only endured but it has positioned itself on top of the coatings heap. It grew from annual sales of $400,000 in 1866 to annual sales topping $15 billion last year, coming from over 100 countries around the world.Its size, scope and quality is one reason hardware giant Lowe's Companies, Inc. (NYSE:LOW) inked a deal to be the only nationwide home seller to offer SHW products. This is even more exciting given that housing demand is back on track and the interest in homeowners to fixing up their current houses. SHW is rated a "B" in my Portfolio Grader system. Vertex (VRTX)Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the leading pharmaceutical firms when it comes to treating cystic fibrosis (CF).Source: Shutterstock That may not seem like much of a franchise given all the other more compelling diseases out there, but VRTX has built a $47.7 billion market cap in the sector and most of its competitors are looking for other places to find an opening.That is a big deal for pharma companies that usually are strong until patents run down or generics start eating into margins. * 7 Value Stocks to Buy for the Second Half Not so with VRTX. As new approvals keep rolling in for next-generation CF drugs, it has plenty more in the pipeline to keep this growth going. Vertex is rated a "B" by Portfolio Grader. Royal Dutch Shell (RDS.A)Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets. With a $226 billion market cap, the only Big Oil that's bigger is Exxon Mobil (NYSE:XOM). It's what is called an integrated energy company because it has operations from the fields to the pipelines to the refineries to the distribution.Source: Mike Mozart via FlickrAs with all energy firms, when times are bad, the more exposure you have to the entire production and distribution process, the tougher things get. But at the size the big oils are, they have the money to wait out the bad patches.And that's just what RDS.A has done. Now it's time to cash in. RDS stock is rated a "C" by Portfolio Grader, but it is still delivering a mouth-watering 6.75% dividend. However, that may wane as the stock price starts rising. In the meanwhile, it's easy to see why this is one of our picks for the best fast-growing stocks. Lumentum (LITE)Lumentum Holdings Inc (NASDAQ: LITE) is a specialty company that focuses on laser beams. It's one of the biggest optical and photonics companies in the world that is working on the 3D sensing sector.Source: Shutterstock Essentially, 3D sensing is basically the gesture sensing that we all have become accustomed with in our mobile devices, screens in our cars, etc. It is one of the most ubiquitous aspects of our interactive age and one of the key parts of the Internet of Things (IoT) concept. * 5 Stocks to Buy for $20 or Less LITE stock rates as a "C" in Portfolio Grader, but the broader tailwinds make it worthwhile. That is to say, Lumentum is also a major player in the optical networking space that makes the infrastructure that makes our world "smarter," operating in as close to real time as possible. It's crucial for the next generation of cloud computing and network operations.Its laser division helps build the next generation of equipment that makes all this possible. Knight-Swift (KNX)Knight-Swift Transportation Holdings Inc (NYSE:KNX) had its humble beginnings in 1966, taking steel from the Port of Los Angeles to Arizona and bringing cotton from Arizona to LA. Today, KNX is a $5.9 billion business with 20,000 trucks on the road throughout the U.S. and Mexico. If you see a Swift logo on a truck while driving, it's a KNX truck.Source: David Guo via FlickrCharles Dow, the inspiration for the Dow Jones Industrial Average, also inspired a fundamental theory about the economy and the markets. It's simply called Dow Theory.One of the core tenants is that if you look at the transportation and the industrial sectors, you can predict how well the economy will be doing in the near future. If the transport business is rising, that's a bullish sign that the economy is on an upswing and KNX stock with it.It's worth mentioning, however, that KNX stock sports an "F" rating in my Portfolio Grader system on a quantitative basis, but it has a "C" rating for fundamentals. Its inclusion in this list lies with its astronomical growth -- KNX stock is up 31% from its January low, and its one-year price target of $42 represents 35% growth. On an earnings basis, Knight-Swift is predicted to grow earnings at a long-term (5-year) rate of 10%.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Check Out These 5 Fast-Growing Stocks to Buy appeared first on InvestorPlace.
Jeffrey Leiden has been the CEO of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) since 2012. This report will...
EVP, Global Research and CSO of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) David Altshuler (insider trades) sold 12,501 shares of VRTX on 08/19/2019 at an average price of $186.38 a share. Continue reading...
But analysts say the rejection could have a ripple effect far outside of the walls of Sarepta's Cambridge headquarters.
Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen. The FDA has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 19, 2020.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Investors know it's not easy to find companies already worth tens of billions that can still expand their revenues rapidly. But these giants show it's not impossible.
If you are looking for fresh investing inspiration, it's worth keeping a close eye on the latest insider activity. That's particularly the case when it comes to insider buy transactions i.e. purchases by company executives or owners. A Harvard study revealed the following: "We find that insider purchases earn abnormal returns of more than 6% per year, and insider sales do not earn significant abnormal returns." As a result the authors conclude that insider buyers 'have a good feel for near-term developments within their firm.'Indeed, if a corporate insider- who arguably has the most in-depth knowledge about their company- decides to reach into their own pocket to buy shares, it is a strong indicator that they see the stock as undervalued at current levels.Here we focus on informative transactions rather than uninformative transactions (ie expiring options) and transactions that occurred in the healthcare sector specifically. As you will all three stocks below also boast a Strong Buy Street consensus, based on analyst ratings published over the last three months. Let's take a closer look now: Align Tech (ALGN)Align Technology has made a big name for itself in the world of orthodontics. The company has revolutionized the use of metal braces with its transparent Invisalign teeth aligner system. According to Align, over 7.2 million people including over 1.7 million teens have benefited from Invisalign. That makes the company the clear market leader in its field. The company faced a wave of insider sell transactions two and three months ago. However, the tide appears to be turning. In the last couple of days, President, CEO and director Joseph Hogan picked up $998 worth of ALGN stock. He now has a total Align holding valued at approximately $31.4 million. What’s more, this is an insider with a relatively strong track record on his Align transactions. He bought shares back in February 2018 at $252; sold at $350 in August of the same year; and is now buying again with the stock back down at $188.Raj Pudipeddi is chief marketing officer of ALGN. He has also just made his first transaction- buying $206,000 worth of shares on August 6.In fact Piper Jaffray analyst Matt O'Brien highlights the CEO transaction, as well as Align entering into an accelerated $200 million stock repurchase plan as evidence of management’s confidence in the business over both the intermediate and long term. This Top 100 analyst believes Align can outperform rivals, telling investors that the company "has much better products that will win in the marketplace." As a result O’Brien reiterated his buy rating and $240 price target.Credit Suisse’s Erin Wright is even more optimistic. She has a Street high price target of $320. “While concerns over competition, DTC concepts, and ASPs will remain overhangs, we view there is room for several players in a highly underpenetrated clear aligner market. ALGN is well ahead in terms of innovation, and we await further traction in recently launched products” says the analyst. While the analyst consensus shows Align as a cautiously optimistic Moderate Buy, if we switch to only the best-performing analysts then the consensus shifts to a more bullish Strong Buy. Indeed out of 7 top-rated analysts covering the stock, 6 rate ALGN a buy. And their $269 average price target suggests considerable upside potential of 46%. Vertex Pharma (VRTX)This groundbreaking biotech specializes in cystic fibrosis (CF) therapies. This is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.Vertex is making important progress in the treatment of the disease. It just submitted a New Drug Application (NDA) to the US FDA for a Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor. “The submission of the NDA is a major step toward our goal of bringing this medicine to the largest remaining group of people with CF that still do not have an approved Vertex medicine, as well as toward providing significantly enhanced benefits to patients with two F508del mutations” Vertex’s chief medical officer wrote following the submission on July 22.And now two insiders have arguably demonstrated their confidence in the application by making large stock purchases. Michael Parini, an exec VP and the company’s chief legal and admin officer, snapped up $201,592 worth of stock this week, bringing his total holding to $6.2 million. Meanwhile chief commercial officer Stuart Arbuckle upped his holding by $330,578 to over $5.7 million. And these insiders aren’t the only financial experts demonstrating bullish sentiment right now. The stock shows a ‘Strong Buy’ Street consensus with 10 out of 12 analysts rating VRTX a buy. That’s with an average price target of $217 (25% upside potential). “Vertex put up another very strong quarter (top- / bottom-line beats) with all three cystic fibrosis assets topping expectations” enthused JP Morgan analyst Cory Kasimov on August 1. “With strong ongoing execution on the CF front, focus continues to turn to the pipeline for the next potential leg of the story. We are finding current stock levels increasingly attractive as 2020 is setting up to be a year of major growth potential both in terms of financial (via early 2020 triple approval) and clinical performance” the analyst told investors. Avrobio (AVRO)Biotech Avrobio is developing lentiviral-based gene therapies that it believes can transform patients' lives in a single dose. Its most advanced pipeline drug is for Fabry disease- a rare inherited disorder that results from the buildup of a particular type of fat in the body's cells. The market opportunity is significant: worldwide sales of roughly $4 billion in 2017 for lysosomal storage diseases (LSDs), which analysts see as Avrobio’s total addressable market.In the last two weeks, both a director and one of the company’s owners have each snapped up a further $15 million of Avrobio stock. That brings director Bruce Booth’s total holding in the company up to a whopping $100 million. Interestingly this is by far his biggest holding, but he does have million-dollar positions in three more biotech stocks: Magenta Therapeutics; Unum Therapeutics; and Miragen Therapeutics. Luckily for Booth, Avrobio has a very bullish outlook from the Street right now. Although only three analysts have published recent AVRO ratings- all three rate the stock a buy. Plus their $34 average price target indicates upside potential of 90%. Top Mizuho Securities analyst Difei Yang reiterated her buy rating and $28 price target on July 16. “We believe AVROBIO's robust clinical development program has potential to demonstrate significant clinical benefits in Fabry patients and ultimately position the company's gene therapy as a first-line treatment” she cheered. Yang made the call after AVRO released positive new trial data showing sustained efficacy and a promising safety profile. Most encouragingly, 3/5 patients treated in the Phase 1 trial have discontinued standard of care enzyme replacement therapy (ERT) so far, added the analyst. Looking forward, additional Fabry updates could be available in late 2019/early 2020 although no specific timeline has yet been provided by management. Discover stocks with positive insider sentiment here
After years as a rare disease drugmaker, Sarepta Therapeutics Inc. is expanding into a neurological disease that affects millions of people worldwide and has been dominated for years by its Cambridge neighbor, Biogen Inc.
EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stuart A Arbuckle (insider trades) sold 3,708 shares of VRTX on 08/05/2019 at an average price of $177.22 a share. Continue reading...